Cited by 421Erythropoietin and Anemia TreatmentBiosimilars and Bioanalytical MethodsHemoglobin structure and function

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin

Open access

Egrie, Joan C, Dwyer, Erik, Browne, Jeffrey K, Hitz, Anna, Lykos, Michele A·2003·Experimental Hematology

Open this paper in CoChat — free account Open PDF

Abstract

Objective Experiments on human erythropoietin (EPO) demonstrated that there is a direct relationship between the sialic acid-containing carbohydrate content of EPO, its circulating half-life, and in vivo bioactivity. This led to the hypothesis that an EPO analogue engineered to contain additional oligosaccharide chains would have enhanced biological activity. Darbepoetin alfa, a hyperglycosylated recombinant human EPO (rHuEPO) analogue with two extra carbohydrate chains, was designed and developed to test this hypothesis. Materials and methods Comparative pharmacokinetic and pharmacodynamic studies and biochemical analyses of darbepoetin alfa and rHuEPO were performed to define the consequences of the increased carbohydrate content. Results Due to its increased sialic acid-containing carbohydrate content, darbepoetin alfa has a higher molecular weight, a greater negative charge, and a approximately fourfold lower EPO receptor binding activity than rHuEPO. It also has a threefold longer circulating half-life than rHuEPO in rats and dogs. In spite of its lower receptor binding, and perhaps counterintuitively, darbepoetin alfa is significantly more potent in vivo than rHuEPO. Due to the pharmacokinetic differences, the relative potency of the two molecules varies as a function of the dosing frequency. Darbepoetin alfa is 3.6-fold more potent than rHuEPO in increasing the hematocrit of normal mice when each is administered thrice weekly, but when the administration frequency is reduced to once weekly, darbepoetin alfa is approximately 13-fold to 14-fold more potent than rHuEPO. Conclusions Increasing the sialic acid-containing carbohydrate content beyond the maximum found in EPO leads to a molecule with a longer circulating half-life and thereby an increased in vivo potency that can be administered less frequently.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0301-472x(03)00006-7

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
THE PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY
Greenwood, F. C., Hunter, W., & GLOVER, J. S. (1963) · Biochemical Journal · doi:10.1042/bj0890114 · Cited by 10,141
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,796
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Hastings, R. C. (1996) · JAMA · doi:10.1001/jama.1996.03540120077042 · Cited by 2,375
Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
Eschbach, J. W., Egrie, J. C., Downing, M. R., Browne, J. K., & Adamson, J. W. (1987) · New England Journal of Medicine · doi:10.1056/nejm198701083160203 · Cited by 1,987
Self-citation
EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSIS
Winearls, C., Pippard, M. J., Downing, M. R., Oliver, D., Reid, C. D. L., & Cotes, P. M. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92192-6 · Cited by 1,401
Applied Biopharmaceutics and Pharmacokinetics.
(1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-94-6-826_2 · Cited by 1,209
Erythropoietin
Krantz, S. B. (1991) · Blood · doi:10.1182/blood.v77.3.419.419 · Cited by 881
Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease: Results of a Phase III Multicenter Clinical Trial
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Self-citation
Expression cloning of the murine erythropoietin receptor
D’Andrea, A. D., Lodish, H. F., & Wong, G. G. (1989) · Cell · doi:10.1016/0092-8674(89)90965-3 · Cited by 737

Show all 47 references

Research works printed but not linked: 1

Sowade, 1998, The safety of treatment with recombinant human erythropoietin in clinical use, Int J Mol Med., 1, 303

Sorted by citations

Items 301–400 of 421

Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia
Wauters, I., Pat, K., & Vansteenkiste, J. (2006) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2006.2.2.175 · Cited by 4
Change in Darbepoetin Alfa Administration Schedule Affects Erythropoiesis-Stimulating Agent Resistance in Patients with Chronic Kidney Disease Receiving Hemodialysis
Molina, M., Navarro, M., de Gracia, C., Álvarez, G., de Alarcón, R., & García, M. Á. (2008) · Renal Failure · doi:10.1080/08860220802248977 · Cited by 4
Basic analytical methods for identification of erythropoiesis-stimulating agents in doping control
Викторович, П. П., Krotov, G. I., Efimova, Y. A., & Rodchenkov, G. M. (2015) · Russian Chemical Reviews · doi:10.1070/rcr4563 · Cited by 4
Biosimilars and their use in hematology and oncology
Waller, C. F. (2012) · Community Oncology · doi:10.1016/j.cmonc.2012.05.004 · Cited by 4
Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase
Aizawa, K., Kawasaki, R., Tashiro, Y., Hirata, M., Endo, K., & Shimonaka, Y. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2000-8 · Cited by 4
Strategies to Develop Therapeutic N- and O-Hyperglycosylated Proteins
Gugliotta, A., Ceaglio, N., Etcheverrigaray, M., Kratje, R. B., & Oggero, M. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7312-5_13 · Cited by 4
The human rhabdomyosarcoma cell line TE671 – Towards an innovative production platform for glycosylated biopharmaceuticals
Rosenlöcher, J., Weilandt, C., Sandig, G., Reinke, S. O., Blanchard, V., & Hinderlich, S. (2015) · Protein Expression and Purification · doi:10.1016/j.pep.2015.08.008 · Cited by 4
Pharmacokinetics of erythropoiesis-stimulating agents
Doshi, S., Ruixo, J. J. P., Jang, G. R., & Chow, A. T. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8698-6_12 · Cited by 4
Every-Other-Week Darbepoetin Alfa in the Correction and Maintenance of Haemoglobin Levels in Elderly Patients with Chronic Kidney Disease
Krause, M. W., Raja, R. M., Agarwal, A. K., Silver, M. R., Scarlata, D., Sciarra, A., & Kewalramani, R. (2009) · Drugs & Aging · doi:10.2165/11316450-000000000-00000 · Cited by 4
Pharmacotherapy of chemotherapy-induced anaemia
Vansteenkiste, J. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.12.2221 · Cited by 4
Characterization of the Hepatic Cellular Uptake of α1-Acid Glycoprotein (AGP), Part 1: A Peptide Moiety of Human AGP Is Recognized by the Hemoglobin β-Chain on Mouse Liver Parenchymal Cells
Nishi, K., Komori, H., Kikuchi, M., Uehara, N., Fukunaga, N., Matsumoto, K., Watanabe, H., Nakajou, K., Misumi, S., Suenaga, A., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22804 · Cited by 4
Darbepoetin Alfa as Primary Prophylaxis of Anemia in Patients with Breast Cancer Treated Preoperatively with Docetaxel/Doxorubicin/Cyclophosphamide
Loibl, S., Kaufmann, M., Maataoui, V., Mehta, K. M., Hofmann, K., Petrich, S., & von Minckwitz, G. (2006) · Supportive Cancer Therapy · doi:10.3816/sct.2006.n.006 · Cited by 4
A Systems Pharmacology Model of Erythropoiesis in Mice Induced by Small Molecule Inhibitor of Prolyl Hydroxylase Enzymes
Singh, I., Nagiec, E. E., Thompson, J., Krzyżański, W., & Singh, P. K. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12 · Cited by 4
In silico design and analysis of a new hyperglycosylated analog of erythropoietin to improve drug efficacy
Omidinia, E., Kianmehr, A., Mohammadi, H., & Shokrgozar, M. A. (2015) · Advanced Biomedical Research · doi:10.4103/2277-9175.161548 · Cited by 4
Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation
Martino, M. V., Lanza, F., Demirer, T., Moscato, T., Secondino, S., & Pedrazzoli, P. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.971749 · Cited by 4
Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease
Agarwal, A. K. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902793031 · Cited by 4
Unveiling the Accurate Site-Specific N- and O-Glycosylation of Hyperglycosylated Erythropoietin Drugs by an Integrated Approach
Wu, S., Lu, J.-H., Tursumamat, N., Liu, Q., Liu, S., Bian, Y., Klein, J., Han, Z., Zaia, J., Lin, C., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c02433 · Cited by 3
Advancements on Substitution of In Vivo Method(s) with In Vitro Method(s) for Recombinant Human Erythropoietin Potency Assays
Garg, N., & Kamal, C. M. (2025) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-025-10688-0 · Cited by 3
Strategies to Enhance Protein Delivery
Zhu, Y., Zhuang, W., & Cheng, H. (2025) · Langmuir · doi:10.1021/acs.langmuir.4c04636 · Cited by 4
Comparative Efficacy and Safety Study of Darbepoetin Alfa versus Epoetin Alfa in Management of Anemia Associated with ESRD in Egyptian Hemodialysis Patients
Ibrahim, A. O., El‐Ashmawy, N. E., Khedr, E. G., Kotb, N. S., & Salem, F. (2021) · Current Drug Safety · doi:10.2174/1568009621666211123095129 · Cited by 3
The MAINTAIN study—managing hemoglobin variability with darbepoetin alfa in dialysis patients experiencing a severe drop in hemoglobin
Watschinger, B., Salmhofer, H., Horn, S., Neyer, U., Wiesinger, T., Wiesholzer, M., Erb, H., Jaeger, C., Hemetsberger, M., & Rosenkranz, A. R. (2013) · Wiener klinische Wochenschrift · doi:10.1007/s00508-012-0311-1 · Cited by 3
Augmentation du transport de l’oxygène par le sang : méthodes et stratégies de détection
Audran, M., & Varlet‐Marie, E. (2004) · Science & Sports · doi:10.1016/j.scispo.2003.09.004 · Cited by 3
A subchronic murine intravenous pharmacokinetic and toxicity study of Hematide™, a PEGylated peptidic erythropoiesis-stimulating agent
Woodburn, K. W., Fan, Q., Schatz, P. J., Wilson, S. D., Fong, K. L., & Norton, D. (2009) · Drug and Chemical Toxicology · doi:10.3109/01480540903176610 · Cited by 3
Current and future options for the treatment of chemotherapy-induced anaemia
Ziegler, J. A., & Herrington, J. D. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.9.1051 · Cited by 3
Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals
Vansteenkiste, J., & Wauters, I. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.10.1347 · Cited by 3
Erythropoietin as an Immunomodulating Agent
Lisowska, K. A., Jasiulewicz, A., Bryl, E., & Witkowski, J. M. (2011) · Nephro-Urology Monthly · Cited by 3
Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report
Ikenoue, T., Naito, H., Kitamura, T., & Hattori, H. (2017) · Journal of Medical Case Reports · doi:10.1186/s13256-017-1468-z · Cited by 3
The Hematopoietic Growth Factors in the Myelodysplastic Syndromes
Ortega, J., Komrokji, R. S., & List, A. F. (2010) · Cancer treatment and research · doi:10.1007/978-1-4419-7073-2_20 · Cited by 3
Hematopoietic Growth Factors in Lung Cancer
Vansteenkiste, J. F., & Dooms, C. A. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-747-5_13 · Cited by 3
Erythropoietin Stimulation and Other Blood Doping Methods
Rhee, J. W., & Erickson, T. B. (2012) · doi:10.1002/9781118105955.ch17 · Cited by 3
Ubiquitous chromatin opening element enhance Darbepoetin alfa expression in CHO DG44 cell line
Hasheminejad, F., Jazayeri, S. H., Halfinezhad, Z., Dalman, A., Daneshipour, A., Emami, B. A., Gharanfoli, M., & Amiri‐Yekta, A. (2024) · Biochemical Engineering Journal · doi:10.1016/j.bej.2024.109468 · Cited by 2
Characterization and application in recombinant N-GlcNAc-protein production of a novel endo-β-N-acetylglucosaminidase from Listeria booriae
Mao, W., Rong, Y., Zhang, H., Fang, Y., Wang, Y., Wang, M., Wang, L., Wang, P. G., Chen, M., Wang, S., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108290 · Cited by 2
Expression of GPI anchored human recombinant erythropoietin in CHO cells is devoid of glycosylation heterogeneity.
Singh, P. K., Devasahayam, M., & Devi, S. (2015) · PubMed · Cited by 2
ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial
Morita, Y., Nannya, Y., Ichikawa, M., Hanamoto, H., Shibayama, H., Maeda, Y., Hata, T., Miyamoto, T., Kawabata, H., Takeuchi, K., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03414-9 · Cited by 2
Quantitative systems pharmacology model of erythropoiesis to simulate therapies targeting anemia due to chronic kidney disease
Roy, M., Saroha, S., Sarma, U., Sarathy, H., & Kumar, R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274490 · Cited by 3
Hematopoietic Growth Factors
Ruixo, J. J. P., & Krzyżański, W. (2024) · Springer eBooks · doi:10.1007/978-3-031-30023-3_17 · Cited by 2
Development and Production of Protein-Based Biotherapeutics in Mammalian Cells
Ceaglio, N., & Oggero, M. (2024) · Topics in medicinal chemistry · doi:10.1007/7355_2024_168 · Cited by 2
Identification and Functional Analysis of Pig β-1,4-N-Acetylglucosaminyltransferase A (MGAT4A)
Kim, J., Hwang, H., Chung, H., Park, M., Byun, S. J., & Kim, K. (2016) · Journal of Life Science · doi:10.5352/jls.2016.26.3.275 · Cited by 2
Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin preparations
JELKMANN, W. E. B. (2008) · Springer eBooks · doi:10.1007/978-3-211-69459-6_16 · Cited by 2
Phase I/II randomised study of a novel erythropoiesis-stimulating agent (AMG 114) for the treatment of anaemia with concomitant chemotherapy in patients with non-myeloid malignancies
BOER, R. D., Clemens, M., Renczes, G., Kotasek, D., Prausová, J., Marschner, N. W., Hedenus, M., Doshi, S., Hendricks, L., & Österborg, A. (2010) · Medical Oncology · doi:10.1007/s12032-010-9725-7 · Cited by 2
Clinical Outcomes Associated with Conversion from Epoetin alfa to Darbepoetin alfa in Hospitalized Hemodialysis Patients
Sarac, E., Chikyarappa, A., Sabol, B., Gemmel, D. J., GLOBE, D. R., Barlev, A., & Audhya, P. (2006) · American Journal of Nephrology · doi:10.1159/000098027 · Cited by 2
Darbepoetin alfa for anemia in chronic kidney disease
Agarwal, A. K. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.3.369 · Cited by 2
Renoprotective effects of erythropoietin
Katavetin, P., Eiam‐Ong, S., & Nangaku, M. (2007) · Asian Biomedicine · doi:10.5372/abm.v1i2.111 · Cited by 2
Detection of Darbepoetin Alfa Misuse in Urine and Blood: A Preliminary Investigation
Shephard, R. J. (2008) · Yearbook of Sports Medicine · doi:10.1016/s0162-0908(08)79184-0 · Cited by 2
Chemoenzymatic synthesis of 6′-sialolactose-modified nanobody
Jiang, M. H., Zhao, J., Mei, G., Han, L., Hong, H., Li, D., & Wu, Z. (2022) · Journal of Carbohydrate Chemistry · doi:10.1080/07328303.2022.2055048 · Cited by 2
Perspectives on Engineering Biobetter Therapeutic Proteins with Greater Stability in Inflammatory Environments
Rao, V. A. (2015) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4939-2543-8_11 · Cited by 2
Non-medical prescribing and anaemia management on the unit
Gerrish, M. (2014) · Journal of Renal Nursing · doi:10.12968/jorn.2014.6.1.10 · Cited by 2
Anemia of Chronic Kidney Disease
El-Kateb, M., & Provenzano, R. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7360-6_6 · Cited by 2
Hematopoietic Growth Factors
Ruixo, J. J. P. (2019) · Springer eBooks · doi:10.1007/978-3-030-00710-2_24 · Cited by 2
Introduction to Hematopoietic Growth Factors
Morstyn, G., & Foote, M. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-747-5_1 · Cited by 2
Unit dosing of darbepoetin alfa for thetreatment of anemia in patients with end-stage renal disease being switched from recombinant human erythropoietin: Results of a phase IIIb, 27-week, multicenter, open-label study in Greek patients
Bristoyiannis, G., Germanos, N., Grekas, D. M., HATZIDIMITRIOU, C., Iatrou, C., Memmos, D., Moutafis, S., Papachristoforou, K., Papadoniou, A., Pappas, M., et al. (2005) · Current Therapeutic Research · doi:10.1016/j.curtheres.2005.06.009 · Cited by 2
Effects of Darbepoetin Alfa Administered Every Two Weeks on Hemoglobin and Quality of Life of Patients Receiving Chemotherapy
Folloder, J. (2005) · Oncology nursing forum · doi:10.1188/05.onf.81-91 · Cited by 2
Impact of Glycosylation on Therapeutic Glycoproteins
Mousavi, M., Dehbashi, M., & Movahedi, A. (2016) · British Journal of Applied Science & Technology · doi:10.9734/bjast/2016/29679 · Cited by 1
Reimagining biomanufacturing: scalable and safe plant-based systems for next-generation biopharmaceuticals
Ko, K. S., Choi, H. N., Yoo, J. Y., & Lee, K. O. (2025) · Plant Biotechnology Reports · doi:10.1007/s11816-025-00993-x · Cited by 1
Host cell impact on pharmacokinetics and neurobiological activity of non-erythropoietic hyperglycosylated EPO variants
Iturraspe, F., Bürgi, M., Fuster, R. G., Kratje, R. B., Scorticati, C., & Oggero, M. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.103901 · Cited by 1
Characterization of the glycosylation profile of erythropoiesis-stimulating agents (ESAs) and impact on potency
TerWee, J. A., McCoy, B., Bernat, B. A., Wilson-Landy, K., Billingham, S., Gulla, K., & Barnes, C. A. S. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.117094 · Cited by 1
Therapeutic timing limitations of postnatal darbepoetin in a valproic acid rat model of Autism Spectrum Disorder
İpek, Ö. Y., Kırboğa, T., Babür, E., Dursun, N., & Süer, C. (2025) · PLoS ONE · doi:10.1371/journal.pone.0337294 · Cited by 1
Darbepoietin alpha ameliorates oxidative/nitrosative stress, decreases apoptosis, and improves clinical outcome in chronic canine monocytic ehrlichiosis
Mahadappa, P., Dey, S., & Saxena, M. (2018) · Comparative Clinical Pathology · doi:10.1007/s00580-018-2818-y · Cited by 1
Efficacy of Darbepoetin alfa in anemic dogs with Chronic Kidney Disease – a review of 21 cases
Baranidharan, G. R., Ramesh, P., Chandrasekar, M., Sumathi, D., Thilagar, B. G., Jeyaraja, K., & Jayathangaraj, M. G. (2019) · International Journal of Hematology and Blood Disorders · doi:10.15226/ijhbd/4/1/00134 · Cited by 1
Biosimilars in rheumatology
Siegel, J. N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00066-8 · Cited by 1
Practical aspects of the use of erythropoiesis-stimulating agent in patients with hematological malignancy
Семочкин, С. В. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-22-1 · Cited by 1
Unravelling the drying techniques of protein biopharmaceuticals
Duarte, S. O. D., Mendonça, A., Condinho, M., & Fonte, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00017-0 · Cited by 1
New molecules and formulations
Elliott, S. G. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8698-6_8 · Cited by 1
Role of Glycosylation in Modulating Therapeutic Efficiency of Protein Pharmaceuticals
Dar, P. A., Manzoor, U., Wani, S. S., Ali, F., & Dar, T. (2019) · Protein Modificomics · doi:10.1016/b978-0-12-811913-6.00006-0 · Cited by 1
The Bittersweet Promise of Glycobiology
Chaudhuri, P., Harfouche, R., & Sengupta, S. (2010) · Biomarkers · doi:10.1002/9780470918562.ch5 · Cited by 1
Improving the Pharmaceutical Properties of Biologics in Drug Discovery: Unique Challenges and Enabling Solutions
Chen, J., & Dongré, A. R. (2012) · doi:10.1002/9781118180778.ch5 · Cited by 1
Glycoengineering of Erythropoietin
Elliott, S. (2009) · doi:10.1002/9783527626601.ch12 · Cited by 1
Haemopoietic growth factors in the treatment of myelodysplastic syndrome
Fra, G. P., & Avanzi, G. C. (2006) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.16.11.1557 · Cited by 1
Spotlight on Darbepoetin??Alfa in the Treatment of Anemia in Patients with Cancer Receiving Chemotherapy1
Siddiqui, M. A. A., & Keating, G. M. (2006) · BioDrugs · doi:10.2165/00063030-200620050-00008 · Cited by 1
Synthesis of Glycopeptides and Glycoproteins
Gamblin, D. P., Scanlan, E. M., & Davis, B. G. (2007) · Elsevier eBooks · doi:10.1016/b978-044451967-2/00016-7 · Cited by 1
Erythropoietin
Schöffel, N. (2011) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-13537 · Cited by 1
Major Classes of Biotherapeutics
Cruz, E., & Kayser, V. (2020) · Wiley eBooks · doi:10.1002/9781119564690.ch4 · Cited by 1
A Randomised Comparison of Darbepoetin alfa with Epoetin for Chemotherapy Induced Anaemia in Nonhaematological Tumours
Kotsori, A. A., & Alexopoulos, C. G. (2006) · Hospital chronicles/Hospital Chronicles · doi:10.2015/hc.v1i1.6
Hematopoietic Growth Factors: Focus on Erythropoiesis-Stimulating Agents
Ruixo, J. J. P., & Chow, A. T. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6486-0_18
Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective
Derbyshire, L., & Thain (2013) · Nursing Research and Reviews · doi:10.2147/nrr.s49399
The Effect of Administering Erythropoiesis‐Stimulating Proteins in Patients With Chronic Heart Failure: Results From a Retrospective Study
Delgado, R. M., Radovancevic, R., van Rossem, C. C., Gaemers, S. J. M., Castanes, S., Adams, S. C., Bracey, A., & Radovančević, B. (2006) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2006.05704.x
Anemia in Chronic Kidney Disease Patients
Rastogi, A., & Nissenson, A. R. (2008) · Transfusion Alternatives in Transfusion Medicine · doi:10.1111/j.1778-428x.2005.tb00119.x
Determination of KRN321 in Rat Serum by ELISA and Correlation Between ELISA andin vitroBioassay
Yoshioka, E., Kato, K., Tanabe, M. G., MISAIZU, T., & Ogata, H. (2006) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321810600734943
Darbepoietin alpha: pharmacokinetics and clinical use in neonates
Ohls, R. K., Dai, A., & Roohi, M. (2009) · Hematology Meeting Reports · doi:10.4081/hmr.v2i10.459
Probing protease sensitivity of recombinant human erythropoietin reveals α3-α4 inter-helical loop as a stability determinant
Samuel, J. S., Kumar, D., Chodisetti, S. B., Agrewala, J. N., Singh, B., Guptasarma, P., & Sarkar, D. (2015) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24865
Drug Development Strategies for Therapeutic Biologics: Industry Perspectives
Yuraszeck, T. M., & Gibbs, M. A. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse559
Cloning and expression of human recombinant erythropoietin in Leishmania tarentolae
Kianmehr, A., Shahbaz Mohammadi, H., & Omidinia, E. (2014) · DOAJ (DOAJ: Directory of Open Access Journals)
Darbepoetin alpha coming of age.
Pedrazzoli, P., Cinieri, S., Lorusso, V., Gamucci, T., Secondino, S., & Silvestris, N. (2007) · PubMed
A Novel Selection Technology for the Discovery of High-Affinity Human Proteins
Busha, D. A. (2014) · CU Scholar (University of Colorado Boulder)
ANEMIA INDUZIDA PELO CANCRO, TRATAMENTO E CONTROVÉRSIAS
Sousa, L. C. N. (2012) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/nsts-3x51
Cost-effectiveness analysis of darbepoetin after switch from epoetin-beta in patients on hemodialysis: an Italian single-center retrospective study
Eandi, M., Giotta, N., Russo, R., & Gianino, M. M. (2006) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v7i1.686
Anemia inducida por quimioterapia en pacientes oncológicos: papel de los
Flores-Balcázar, C. H. (2015) · Dialnet (Universidad de la Rioja)
Introduction
Aapro, M., & Fahey, T. J. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.04.001
Pharmocokinetic and pharmacodynamic modeling of erythropoiesis stimulating agents in rats
Hrebien, L., Kam, M., & Chen, W. (2011)
Optimizing the glycosylation of recombinant proteins
Rosenlöcher, J. (2016) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-8398
A randomized comparison of darbepoetin alfa with epoetin for chemotherapy induced anemia in nonhematological tumors
Kotsori, A. A., & Alexopoulos, C. G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.18554
AVALIAÇÃO DE ERITROPOIETINA HUMANA RECOMBINANTEPOR MÉTODOS CROMATOGRÁFICOS VALIDADOS ECORRELAÇÃO COM O BIOENSAIO
Ferretto, R. M. (2009) · Americanae (AECID Library)
Glycoengineering of Chinese Hamster Ovary cells for improving biotherapeutics’ efficacies.
Chung, C. (2016)
SYNERKINE | IL4-10 fusion protein for the treatment of inflammatory diseases
Louws, C. (2020) · doi:10.33540/396
A potent erythropoietin mimic human antibody interacts through a novel binding site Running titile: EPOR AB ACTIVATES THROUGH A NOVEL BINDING SITE
Egan, D. A., Harlan, J. E., Lesniewski, R. R., Reilly, E. B., Liu, Z., Stoll, V. S., DeVries, P. J., Jakob, C. G., Xie, N., Simmer, R. L., et al. (2007)
ASXL1 Mutations with Serum EPO Levels Predict a Poor Response to Darbepoetin Alfa in Lower-Risk MDS: W-JHS MDS01 TrialPreprint
Morita, Y., Nannya, Y., Ichikawa, M., Hanamoto, H., Shibayama, H., Maeda, Y., Hata, T., Miyamoto, T., Kawabata, H., Takeuchi, K., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-957642/v1
LC-MS techniques for analytical testing of recombinant human erythropoietin and darbepoetin alfa in equine plasma samples for anti-doping control
Phung, K. (2008) · doi:10.31274/rtd-180813-16610
Glycoengineering of Darbepoetin-α in CHO-DG44 Cells through Overexpression of α-2,3-sialyl-transferase and CMP-sialic Acid Transporter
Santoso, A., Septisetyani, E. P., Ramadani, R. D., Rubiyana, Y., Prasetyaningrum, P. W., Wisnuwardhani, P. H., Kusumawati, A., & Nuraini, N. (2022) · HAYATI Journal of Biosciences · doi:10.4308/hjb.29.2.204-213
Pharmacokinetics
Shibata, N., Ιtο, Y., & Takada, K. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse314
Glycosylation
Spearman, M. A., Lattová, E., Perreault, H., & Butler, M. (2018) · Wiley eBooks · doi:10.1002/9781119378341.ch3

Authors: Egrie, J. C., Dwyer, E., Browne, J. K., Hitz, A., & Lykos, M. A.
Affiliations: Amgen (United States) (US)
Corresponding author: Egrie, Joan C
Venue: Experimental Hematology
Publisher: Elsevier BV
Published: 2003-04
Volume: 31
Issue: 4
Pages: 290-299
ISSN: 0301-472X (ISSN-L)
DOI: 10.1016/s0301-472x(03)00006-7
OpenAlex: W2169177790
Cited by: 421
References: 47
Citations by year: 2026: 10 · 2025: 14 · 2024: 6 · 2023: 7 · 2022: 11 · 2021: 12 · 2020: 3 · 2019: 12 · 2018: 14 · 2017: 12 · 2016: 13 · 2015: 19 · 2014: 16 · 2013: 16 · 2012: 19
FWCI: 16.09
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 7008 d)
Locations: Experimental Hematology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
Keywords: darbepoetin alfa, recombinant human erythropoietin, erythropoietin analogues, hyperglycosylation, serum half-life, in vivo potency, hematocrit, dosing frequency, pharmacokinetics, pharmacodynamics
MeSH terms: Darbepoetin alfa, Animals, Carbohydrates, Dogs, Dose-Response Relationship, Drug, Electrochemistry, Electrophoresis, Polyacrylamide Gel, Erythropoietin, Half-Life, Hematocrit, Humans, Kinetics, Male, Molecular Weight, Recombinant Proteins, Rats, Sprague-Dawley, Receptors, Erythropoietin, N-Acetylneuraminic Acid, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks